<!doctype html>
<html lang="en"><head>
<meta charset="utf-8"/><meta name="viewport" content="width=device-width,initial-scale=1"/>
<link rel="stylesheet" href="/Newsletter/style.css"/>
<title>NKTR Shares Surge 38.2% in a Week: Here&#x27;s What You Should Know — Newsletter</title>
</head><body>
<div class="container">
  <div class="header">
    <h1 style="margin:0;font-size:28px">Newsletter</h1>
    <a class="btn" href="/Newsletter/">Home</a>
  </div>
  <div class="card">
    <h2 style="margin-top:0">NKTR Shares Surge 38.2% in a Week: Here&#x27;s What You Should Know</h2>
    <div class="badge">2025-09-08T15:27:00+00:00</div>
    <ul>
      <li>Year to date, shares of Nektar have surged 188.1% compared with the industry’s rise of 14.1%.</li>
<li>The company expects to advance rezpeg into phase III development in the first half of 2026.</li>
<li>Shares of Nektar Therapeutics NKTR have rallied 38.2% in the past week due to growing investor optimism related to the company’s lead pipeline candidate, rezpegaldesleukin (rezpeg), which is being developed as a self-adm</li>
<li>Image Source: Zacks Investment Research NKTR’s Atopic Dermatitis Data on Rezpeg In June 2025, NKTR announced that the phase IIb REZOLVE-AD study evaluating rezpeg in patients with moderate-to-severe atopic dermatitis met</li>
<li>Despite amlitelimab meeting all primary and key secondary endpoints in the COAST 1 study, shares of SNY tanked as the data seemed to fall short of investors&#x27; expectations.</li>
<li>Here’s Why NKTR Was Up This Past Week Nektar’s price rose after French drugmaker Sanofi SNY announced data from the phase III COAST 1 study evaluating its pipeline candidate, amlitelimab, for treating moderate-to-severe</li>
<li>However, rezpeg’s long-term efficacy is yet to be determined.</li>
    </ul>
    <p>
      <a class="btn" href="https://x.com/intent/tweet?text=NKTR%20Shares%20Surge%2038.2%25%20in%20a%20Week%3A%20Here%27s%20What%20You%20Should%20Know%0A%E2%80%A2%20Year%20to%20date%2C%20shares%20of%20Nektar%20have%20surged%20188.1%25%20compared%20with%20the%20industry%E2%80%99s%20rise%20of%2014.1%25.%0A%E2%80%A2%20The%20company%20expects%20to%20advance%20rezpeg%20into%20phase%20III%20development%20in%20the%20first%20half%20of%202026.%0A%E2%80%A2%20Shares%20of%20Nektar%20Therapeutics%20NKTR%20have%20rallied%2038.2%25%20in%20the%20past%20week%20due%20to%20growing%20investor%20optimism%20related%20to%20the%20company%E2%80%99s%20lead%20pipeline%20candidate%2C%20rezpegaldesleukin%20%28rezpeg%29%2C%20which%20is%20being%20developed%20as%20a%20self-adm%0A%E2%80%A2%20Image%20Source%3A%20Zacks%20Investment%20Research%20NKTR%E2%80%99s%20Atopic%20Dermatitis%20Data%20on%20Rezpeg%20In%20June%202025%2C%20NKTR%20announced%20that%20the%20phase%20IIb%20REZOLVE-AD%20study%20evaluating%20rezpeg%20in%20patients%20with%20moderate-to-severe%20atopic%20dermatitis%20met%0A%E2%80%A2%20Despite%20amlitelimab%20meeting%20all%20primary%20and%20key%20secondary%20endpoints%20in%20the%20COAST%201%20study%2C%20shares%20of%20SNY%20tanked%20as%20the%20data%20seemed%20to%20fall%20short%20of%20investors%27%20expectations.%0A%E2%80%A2%20Here%E2%80%99s%20Why%20NKTR%20Was%20Up%20This%20Past%20Week%20Nektar%E2%80%99s%20price%20rose%20after%20French%20drugmaker%20Sanofi%20SNY%20announced%20data%20from%20the%20phase%20III%20COAST%201%20study%20evaluating%20its%20pipeline%20candidate%2C%20amlitelimab%2C%20for%20treating%20moderate-to-severe%0A%E2%80%A2%20However%2C%20rezpeg%E2%80%99s%20long-term%20efficacy%20is%20yet%20to%20be%20determined.&url=https%3A%2F%2Fsuavir600.github.io%2FNewsletter%2Farticles%2Fnktr-shares-surge-38-2-in-a-week-here-s-what-you-should-know%2F" target="_blank" rel="noopener">Tweet bullets</a>
      &nbsp;&nbsp;
      <a class="btn" href="https://finance.yahoo.com/news/nktr-shares-surge-38-2-152700121.html" target="_blank" rel="noopener nofollow">finance.yahoo.com</a>
    </p>
  </div>
  <div class="footer">Built from digest_5bullets.md</div>
</div>
</body></html>